Mainz Biomed (NASDAQ:MYNZ) Shares Down 5.3% – Here’s Why

Mainz Biomed (NASDAQ:MYNZ) traded down 5.3% on Wednesday . The company traded as low as $4.24 and last traded at $4.32. 53,969 shares changed hands during trading, an increase of 22% from the average session volume of 44,295 shares. The stock had previously closed at $4.56.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered shares of Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday, November 25th.

Mainz Biomed Price Performance

The stock has a market capitalization of $8.64 million, a PE ratio of -0.07 and a beta of 0.06. The business has a 50 day moving average price of $7.66 and a 200 day moving average price of $11.82.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.